The MUHC salutes the government of Quebec's commitment to research and innovation
Dr. Arthur T. Porter, Director General and CEO of the McGill University Health Centre (MUHC), expressed his satisfaction upon learning today that the Government of Quebec had launched a Quebec strategy for research and innovation.
Dr. Arthur T. Porter, Director General and CEO of the McGill University Health Centre (MUHC), expressed his satisfaction upon learning today that the Government of Quebec had launched a Quebec strategy for research and innovation, starting with an additional $888 million in funding, for a total investment of $1.2 billion, and a focus on the value and transfer of knowledge.
"This announcement, which comes on the heels of our recruiting internationally respected scientist Dr. Vassilios Papadopoulos to lead the Research Institute of the MUHC, sends a strong signal to Canada and the world that this government intends for Quebec to contribute concretely to research and innovation," declared Dr. Arthur T. Porter.
An investment and strategy of this nature provides the right environment to attract and retain leading researchers, as well as ensure their discoveries benefit people at home and around the world. The MUHC encourages all strategies that help propel medical discoveries into patient benefits, at home and around the world, as quickly as possible.
That commitment requires vision. Earlier this year, this vision translated into the launch of the Excellerator, an MUHC-McGill strategy co-chaired by Senator Céline Hervieux-Payette and Senator W. David Angus, to create the right environment to translate life sciences innovation from bench to bedside and maximize socio-economic benefits. The MUHC also appointed Dr. Vassilios Papadopoulos, former Associate Vice-President and Director of Georgetown University Medical Center in Washington, D.C., as the new Director of its Research Institute.
"This announcement confirms the importance that Quebec accords to the pursuit of excellence in biomedical sciences," stated Dr. Vassilios Papadopoulos, Director of the Research Institute of the MUHC and Associate Executive Director for Research at the MUHC. "As a scientist and research administrator, I am delighted with my decision to come to Montreal. I look forward to building on the MUHC's successes and commitment to excellence."
About the McGill University Health Centre
The MUHC is a comprehensive academic health institution with an international reputation for excellence in clinical programs, research, teaching and technology evaluation. The MUHC is a merger of five teaching hospitals affiliated with the Faculty of Medicine at McGill University: the Montreal Children's, Montreal General, Royal Victoria, and Montreal Neurological hospitals, and the Montreal Chest Institute. Building on the tradition of medical leadership of the founding hospitals, the goal of the MUHC is to provide patient care based on the most advanced knowledge in the health care field and to contribute to the development of new knowledge. www.muhc.ca
The Research Institute of the McGill University Health Centre (RI MUHC) is a world-renowned biomedical and health care, hospital-based research centre. Located in Montreal, Quebec, the Institute is the research arm of the MUHC, a university health centre affiliated with the Faculty of Medicine at McGill University. The Institute supports over 500 researchers, nearly 1,000 graduate and post-doctoral students, and operates more than 300 laboratories devoted to a broad spectrum of fundamental and clinical research. The Research Institute operates at the forefront of knowledge, innovation and technology and is inextricably linked to the clinical programs of the MUHC, ensuring that patients benefit directly from the latest research-based knowledge. For further details visit: www.muhc.ca/research.
For more information, contact: